Heparin/lidocaine/sodium bicarbonate

Drug Profile

Heparin/lidocaine/sodium bicarbonate

Alternative Names: Alkalised lidocaine and heparin formulation - Urigen Pharmaceuticals; Compounded alkalinised lidocaine and heparin - Imprimis; Hep-Lido-A compounded formulation; U 101; URG-101

Latest Information Update: 07 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Urigen Pharmaceuticals
  • Class Acetanilides; Alkalinising agents; Heparins; Local anaesthetics; Small molecules; Urologics
  • Mechanism of Action Factor Xa inhibitors; Sodium channel antagonists; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Interstitial cystitis
  • Discontinued Cystitis; Dyspareunia

Most Recent Events

  • 18 May 2015 Efficacy and pharmacokinetics data from a clinical trial in Interstitial cystitis released by Imprimis Pharmaceuticals
  • 08 May 2015 Imprimis has patent protection for heparin/lidocaine/sodium bicarbonate compounded formulation in USA
  • 28 Apr 2015 Imprimis notified Urigen of its intent to convert its commercial rights of heparin/lidocaine/sodium bicarbonate to exclusive
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top